Loading...

Elekta

OTCPK:EKTA.F
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EKTA.F
OTCPK
SEK49B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The last earnings update was 26 days ago. More info.


Add to Portfolio Compare Print
EKTA.F Share Price and Events
7 Day Returns
1.1%
OTCPK:EKTA.F
3%
US Medical Equipment
2%
US Market
1 Year Returns
6.2%
OTCPK:EKTA.F
16.5%
US Medical Equipment
4.3%
US Market
EKTA.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Elekta (EKTA.F) 1.1% 22.1% 9.1% 6.2% 78.8% 8.1%
US Medical Equipment 3% 8.1% 5.6% 16.5% 68.9% 101.1%
US Market 2% 4.1% 4.2% 4.3% 43.9% 40.8%
1 Year Return vs Industry and Market
  • EKTA.F underperformed the Medical Equipment industry which returned 16.5% over the past year.
  • EKTA.F outperformed the Market in United States of America which returned 4.3% over the past year.
Price Volatility
EKTA.F
Industry
5yr Volatility vs Market

EKTA.F Value

 Is Elekta undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Elekta to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Elekta.

OTCPK:EKTA.F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 12 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:EKTA.F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.85
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.852 (1 + (1- 22%) (9.32%))
0.942
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.94
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.942 * 5.96%)
8.35%

Discounted Cash Flow Calculation for OTCPK:EKTA.F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Elekta is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:EKTA.F DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 8.35%)
2019 803.80 Analyst x4 741.88
2020 1,643.20 Analyst x5 1,399.78
2021 2,077.00 Analyst x6 1,633.02
2022 2,610.80 Analyst x5 1,894.58
2023 2,727.00 Analyst x1 1,826.45
2024 3,219.00 Analyst x1 1,989.89
2025 3,545.57 Est @ 10.14% 2,022.92
2026 3,826.39 Est @ 7.92% 2,014.96
2027 4,069.88 Est @ 6.36% 1,978.08
2028 4,284.50 Est @ 5.27% 1,921.97
Present value of next 10 years cash flows SEK17,423.51
OTCPK:EKTA.F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= SEK4,284.50 × (1 + 2.73%) ÷ (8.35% – 2.73%)
SEK78,364.94
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK78,364.94 ÷ (1 + 8.35%)10
SEK35,153.46
OTCPK:EKTA.F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK17,423.51 + SEK35,153.46
SEK52,576.97
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK52,576.97 / 382.03
SEK137.63
OTCPK:EKTA.F Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in OTCPK:EKTA.F represents 0.10777x of OM:EKTA B
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.10777x
Value per Share
(Listing Adjusted, USD)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 137.63 x 0.10777
$14.83
Value per share (USD) From above. $14.83
Current discount Discount to share price of $13.80
= -1 x ($13.80 - $14.83) / $14.83
7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Elekta is available for.
Intrinsic value
7%
Share price is $13.8 vs Future cash flow value of $14.83
Current Discount Checks
For Elekta to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Elekta's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Elekta's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Elekta's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Elekta's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:EKTA.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-04-30) in SEK SEK3.14
OM:EKTA B Share Price ** OM (2019-06-21) in SEK SEK128.05
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 41.58x
United States of America Market PE Ratio Median Figure of 3,095 Publicly-Listed Companies 17.88x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Elekta.

OTCPK:EKTA.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:EKTA B Share Price ÷ EPS (both in SEK)

= 128.05 ÷ 3.14

40.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Elekta is good value based on earnings compared to the US Medical Equipment industry average.
  • Elekta is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Elekta's expected growth come at a high price?
Raw Data
OTCPK:EKTA.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 40.83x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts
18%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 56 Publicly-Listed Medical Equipment Companies 2.32x
United States of America Market PEG Ratio Median Figure of 2,134 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

OTCPK:EKTA.F PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 40.83x ÷ 18%

2.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Elekta is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Elekta's assets?
Raw Data
OTCPK:EKTA.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-04-30) in SEK SEK20.36
OM:EKTA B Share Price * OM (2019-06-21) in SEK SEK128.05
United States of America Medical Equipment Industry PB Ratio Median Figure of 183 Publicly-Listed Medical Equipment Companies 4.6x
United States of America Market PB Ratio Median Figure of 5,255 Publicly-Listed Companies 1.8x
OTCPK:EKTA.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:EKTA B Share Price ÷ Book Value per Share (both in SEK)

= 128.05 ÷ 20.36

6.29x

* Primary Listing of Elekta.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Elekta is overvalued based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Elekta's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Elekta has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

EKTA.F Future Performance

 How is Elekta expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Elekta expected to grow at an attractive rate?
  • Elekta's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Elekta's earnings growth is expected to exceed the United States of America market average.
  • Elekta's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:EKTA.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:EKTA.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 18%
OTCPK:EKTA.F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 12 Analysts 9%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.9%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:EKTA.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:EKTA.F Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-04-30 21,051 4,135 3,285 2
2023-04-30 19,638 3,577 2,892 2
2022-04-30 18,852 3,320 2,298 7
2021-04-30 16,591 2,716 1,915 12
2020-04-30 15,259 2,357 1,527 10
OTCPK:EKTA.F Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-04-30 13,555 1,621 1,198
2019-01-31 12,637 1,307 915
2018-10-31 12,075 2,056 1,046
2018-07-31 11,648 1,947 1,066
2018-04-30 11,333 2,404 1,099
2018-01-31 11,879 2,393 939
2017-10-31 11,795 2,095 639
2017-07-31 11,326 2,034 389
2017-04-30 10,704 1,819 125
2017-01-31 10,596 1,442 108
2016-10-31 10,470 1,375 70
2016-07-31 10,864 1,380 203

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Elekta's earnings are expected to grow by 18% yearly, however this is not considered high growth (20% yearly).
  • Elekta's revenue is expected to grow by 9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:EKTA.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from Elekta Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:EKTA.F Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-04-30 8.60 8.60 8.60 1.00
2023-04-30 7.57 7.57 7.57 1.00
2022-04-30 5.97 7.13 4.79 7.00
2021-04-30 4.96 6.15 3.88 10.00
2020-04-30 3.97 4.38 3.59 10.00
OTCPK:EKTA.F Past Financials Data
Date (Data in SEK Millions) EPS *
2019-04-30 3.14
2019-01-31 2.40
2018-10-31 2.74
2018-07-31 2.79
2018-04-30 2.88
2018-01-31 2.46
2017-10-31 1.67
2017-07-31 1.02
2017-04-30 0.33
2017-01-31 0.28
2016-10-31 0.18
2016-07-31 0.53

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Elekta is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Elekta's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Elekta has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

EKTA.F Past Performance

  How has Elekta performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Elekta's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Elekta's year on year earnings growth rate has been positive over the past 5 years.
  • Elekta's 1-year earnings growth exceeds its 5-year average (9% vs 4.1%)
  • Elekta's earnings growth has not exceeded the US Medical Equipment industry average in the past year (9% vs 31.9%).
Earnings and Revenue History
Elekta's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Elekta Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:EKTA.F Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-04-30 13,555.00 1,198.00 2,335.00 1,592.00
2019-01-31 12,637.00 915.00 2,277.00 1,409.00
2018-10-31 12,075.00 1,046.00 2,229.00 1,273.00
2018-07-31 11,648.00 1,066.00 2,197.00 1,144.00
2018-04-30 11,333.00 1,099.00 2,156.00 1,095.00
2018-01-31 11,879.00 939.00 2,125.00 1,147.00
2017-10-31 11,795.00 639.00 2,129.00 1,144.00
2017-07-31 11,326.00 389.00 2,150.00 1,083.00
2017-04-30 10,704.00 125.00 2,093.00 1,018.00
2017-01-31 10,596.00 108.00 2,139.00 977.00
2016-10-31 10,470.00 70.00 2,200.00 991.00
2016-07-31 10,864.00 203.00 2,238.00 1,044.00
2016-04-30 11,221.00 137.00 2,362.00 1,065.00
2016-01-31 11,469.00 402.00 2,548.00 1,070.00
2015-10-31 11,474.00 548.00 2,526.00 1,022.00
2015-07-31 11,213.00 558.00 2,485.00 974.00
2015-04-30 10,839.00 552.00 2,383.00 952.00
2015-01-31 10,938.00 1,029.00 2,097.00 904.00
2014-10-31 10,771.00 1,026.00 2,027.00 902.00
2014-07-31 10,647.00 1,017.00 1,999.00 896.00
2014-04-30 10,694.00 1,148.00 1,974.00 866.00
2014-01-31 10,471.00 1,173.00 1,964.00 805.00
2013-10-31 10,514.00 1,256.00 1,993.00 778.00
2013-07-31 10,556.00 1,322.00 2,019.00 736.00
2013-04-30 10,339.00 1,340.00 2,025.00 715.00
2013-01-31 9,727.00 1,041.00 2,039.00 736.00
2012-10-31 9,864.00 1,201.00 2,023.00 690.00
2012-07-31 9,315.00 1,192.00 1,936.00 664.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Elekta has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Elekta used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.
  • Elekta has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Elekta's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Elekta has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

EKTA.F Health

 How is Elekta's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Elekta's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Elekta is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Elekta's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Elekta's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Elekta Company Filings, last reported 1 month ago.

OTCPK:EKTA.F Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-04-30 7,779.00 4,558.00 4,118.00
2019-01-31 7,254.00 4,501.00 2,981.00
2018-10-31 6,970.00 4,958.00 3,669.00
2018-07-31 6,843.00 4,854.00 3,547.00
2018-04-30 7,975.00 5,341.00 4,541.00
2018-01-31 7,040.00 5,063.00 3,612.00
2017-10-31 6,734.00 5,149.00 3,214.00
2017-07-31 6,511.00 5,071.00 3,158.00
2017-04-30 6,774.00 5,268.00 3,383.00
2017-01-31 6,422.00 5,130.00 2,284.00
2016-10-31 6,581.00 5,180.00 2,121.00
2016-07-31 6,529.00 5,092.00 2,060.00
2016-04-30 6,412.00 4,949.00 2,273.00
2016-01-31 6,432.00 5,047.00 1,683.00
2015-10-31 6,650.00 5,041.00 1,586.00
2015-07-31 6,835.00 6,151.00 2,748.00
2015-04-30 6,646.00 6,032.00 3,265.00
2015-01-31 6,226.00 5,036.00 1,011.00
2014-10-31 5,847.00 4,665.00 942.00
2014-07-31 6,357.00 4,600.00 1,595.00
2014-04-30 6,257.00 4,484.00 2,247.00
2014-01-31 5,302.00 4,499.00 1,199.00
2013-10-31 5,056.00 4,419.00 1,173.00
2013-07-31 5,535.00 4,459.00 1,826.00
2013-04-30 5,560.00 4,549.00 2,567.00
2013-01-31 4,756.00 4,376.00 1,554.00
2012-10-31 4,699.00 4,485.00 1,589.00
2012-07-31 4,824.00 4,545.00 1,642.00
  • Elekta's level of debt (58.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (71.7% vs 58.6% today).
  • Debt is well covered by operating cash flow (35.6%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 14.2x coverage).
X
Financial health checks
We assess Elekta's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Elekta has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

EKTA.F Dividends

 What is Elekta's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.41%
Current annual income from Elekta dividends. Estimated to be 1.61% next year.
If you bought $2,000 of Elekta shares you are expected to receive $28 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Elekta's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).
  • Elekta's dividend is below the markets top 25% of dividend payers in United States of America (3.73%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:EKTA.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2012 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:EKTA.F Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2024-04-30 3.40 1.00
2023-04-30 3.03 1.00
2022-04-30 2.32 7.00
2021-04-30 1.99 11.00
2020-04-30 1.75 11.00
OTCPK:EKTA.F Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2019-05-29 1.800 1.418
2018-08-09 1.400 1.224
2018-06-01 1.400 1.179
2017-08-23 1.000 1.241
2016-08-11 0.500 0.616
2016-06-01 0.500 0.760
2015-09-01 0.500 0.794
2014-08-28 2.000 2.865
2013-09-03 1.500 1.628
2012-08-06 1.250 1.286
2012-04-05 1.000 1.201
2011-08-23 1.000 1.411
2011-06-09 1.000 1.459
2010-08-23 0.750 1.182
2009-09-15 0.500 1.137

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Elekta's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.7x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (2.7x coverage).
X
Income/ dividend checks
We assess Elekta's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Elekta afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Elekta has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

EKTA.F Management

 What is the CEO of Elekta's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Richard Hausmann
COMPENSATION SEK14,820,000
AGE 58
TENURE AS CEO 3 years
CEO Bio

Dr. Richard Hausmann, Ph.D. has been the Chief Executive Officer and President of Elekta AB (publ) since June 10, 2016. Dr. Hausmann has been Vice President at General Electric Company since January 1, 2012. He served as Chief Executive Officer and President of the Global MR Business for GE Healthcare Limited since December 2011 until October 2014. Dr. Hausmann served as General Manager of Magnetic Resonance (MR) Business at GE Healthcare Limited since January 1, 2012. He joined GE Healthcare from Siemens AG Energy. Dr. Hausmann served as Head of Smart Grid Applications at Siemens Aktiengesellschaft and served as its Head of Operations in China since January 1, 2005. He served as the Chief Executive Officer and President of Siemens Ltd., China since January 1, 2005 and also served as its Member of the Management Board. He served as President and Chief Executive Officer of cluster of Siemens North Asia for five years. He has a commercial background in healthcare, serving as President and Chief Executive Officer of the Siemens Healthcare CT business as well as Vice President of Marketing and Sales, CT. Dr. Hausmann was responsible for Siemens Groups Power Generation, Power Transmission and Distribution, Transportation Systems, Medical Solutions as well as the departments Corporate Communication, Strategic Planning & Corporate Development, Government Relations and Corporate Technology. He served as the president and Chief Executive Officer, Computed Tomography for the Siemens Medical Solutions Group and led the Medical Engineering Group as the Vice President of Strategy, Marketing and Sales & Product Planning. He joined Siemens Medical Engineering Group in June 1988. He served in the Applications Development Department of the Magnetic Resonance (MR) Division. until 1993. From 1994 to 1995, Dr. Hausmann served as Marketing Manager for the new Magnetom Open MR system. In 1995, he served as Manager of MR Applications Development and Director for Marketing and Product Planning. He joined the Computer Tomography (CT) Division in 1998, where he served as Division President since April 2000 and was also responsible for the China business of Siemens Medical Solutions Group. Dr. Hausmann served as Head of Siemens Ag's Computer Tomography Division. He published numerous articles on modern applications of Magnetic Resonance and holds various patents related to Magnetic Resonance and Imaging. In 1988, he completed his studies with a Doctorate in Physics at Regensburg University, Germany. Dr. Hausmann studied Physics at the State University of New York at Stony Brook.

CEO Compensation
  • Richard's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.
  • Richard's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Elekta management team in years:

1.9
Average Tenure
52
Average Age
  • The average tenure for the Elekta management team is less than 2 years, this suggests a new team.
Management Team

Laurent Leksell

TITLE
Founder & Chairman
COMPENSATION
SEK1M
AGE
66

Richard Hausmann

TITLE
President & CEO
COMPENSATION
SEK15M
AGE
58
TENURE
3 yrs

Gustaf Salford

TITLE
CFO & Executive VP
AGE
41
TENURE
1.9 yrs

Steve Wort

TITLE
COO & Group VP of Manufacturing & Logistics
AGE
55
TENURE
1.8 yrs

John Lapré

TITLE
Chief Technology Officer
AGE
54
TENURE
3.1 yrs

Cecilia Ketels

TITLE
Head of Investor Relations
TENURE
0.1 yrs

Caroline Mofors

TITLE
Senior VP
AGE
46
TENURE
4.8 yrs

Jonas Bolander

TITLE
General Counsel & Executive VP
AGE
52
TENURE
2.6 yrs

Oskar Bosson

TITLE
Executive Vice President of Corporate Communications & Investor Relations
AGE
42
TENURE
1.3 yrs

Ioannis Panagiotelis

TITLE
Chief Marketing & Sales Officer
AGE
46
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure and age of the Elekta board of directors in years:

6.1
Average Tenure
61
Average Age
  • The tenure for the Elekta board of directors is about average.
Board of Directors

Laurent Leksell

TITLE
Founder & Chairman
COMPENSATION
SEK1M
AGE
66
TENURE
5.8 yrs

Birgitta Göransson

TITLE
Independent Director
COMPENSATION
SEK710K
AGE
61
TENURE
14.4 yrs

Tomas Puusepp

TITLE
Non-Executive Director
COMPENSATION
SEK7M
AGE
63
TENURE
6.4 yrs

Luciano Cattani

TITLE
Independent Director
COMPENSATION
SEK560K
AGE
73
TENURE
10.8 yrs

Jan Secher

TITLE
Independent Director
COMPENSATION
SEK620K
AGE
61
TENURE
9.4 yrs

Wolfgang Reim

TITLE
Independent Director
COMPENSATION
SEK485K
AGE
62
TENURE
8.4 yrs

Johan Malmquist

TITLE
Independent Director
COMPENSATION
SEK560K
AGE
57
TENURE
4.4 yrs

Annika Jansson

TITLE
Independent Director
COMPENSATION
SEK620K
AGE
54
TENURE
4.4 yrs

Caroline Cooke

TITLE
Independent Director
COMPENSATION
SEK485K
AGE
37
TENURE
1.8 yrs

Cecilia Wikström

TITLE
Director
AGE
53
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
27. Feb 19 Buy Jan Secher Individual 26. Feb 19 26. Feb 19 10,000 $11.79 $117,313
X
Management checks
We assess Elekta's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Elekta has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

EKTA.F News

Simply Wall St News

EKTA.F Company Info

Description

Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; microSelectron, a digital pulsed dose rate platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Elekta Neuromag TRIUX, a magnetoencephalography system; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.

Details
Name: Elekta AB (publ)
EKTA.F
Exchange: OTCPK
Founded: 1972
SEK5,264,583,508
382,027,041
Website: http://www.elekta.com
Address: Elekta AB (publ)
Box 7593,
Stockholm,
Stockholm County, 103 93,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM EKTA B Series B Registered Shares OMX Nordic Exchange Stockholm SE SEK 02. Mar 1994
OTCPK EKTA.F Series B Registered Shares Pink Sheets LLC US USD 02. Mar 1994
DB EJXB Series B Registered Shares Deutsche Boerse AG DE EUR 02. Mar 1994
LSE 0O5H Series B Registered Shares London Stock Exchange GB SEK 02. Mar 1994
BATS-CHIXE EKTABS Series B Registered Shares BATS 'Chi-X Europe' GB SEK 02. Mar 1994
OTCPK EKTA.Y UNSPONSOD ADR Pink Sheets LLC US USD 08. Dec 2008
Number of employees
Current staff
Staff numbers
4,000
Elekta employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/24 23:50
End of day share price update: 2019/06/21 00:00
Last estimates confirmation: 2019/06/20
Last earnings filing: 2019/05/29
Last earnings reported: 2019/04/30
Last annual earnings reported: 2019/04/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.